Anthony Polcari, MD
Urology · Woodbury, MNNPI 1629241062
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Immunitybio, Inc. at 36.5% of the total.
Across 46 payments — averaging $150.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunitybio, Inc.$3K
- Boston Scientific$2K
- Procept Biorobotics Corporation$1K
- Olympus America Inc.$183
- Tempus AI, Inc$119
- Tolmar Pharmaceuticals, Inc.$50
- plus $540 from 19 others
What the payments were for
- Consulting fees$1,50022%
- Speaking & faculty fees$2,50036%
- Travel & lodging$1,83927%
- Food & beverage$99814%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunitybio, Inc. | 3 | $2,525 |
| Boston Scientific | 7 | $2,246 |
| Procept Biorobotics Corporation | 3 | $1,259 |
| Olympus America Inc. | 3 | $183 |
| Tempus AI, Inc | 1 | $119 |
| Tolmar Pharmaceuticals, Inc. | 1 | $50 |
| AstraZeneca | 2 | $49 |
| Coloplast | 3 | $46 |
| Progenics Pharmaceuticals, Inc. | 3 | $46 |
| Angiodynamics, Inc. | 1 | $46 |
| Astellas Pharma US Inc | 3 | $45 |
| Teleflex LLC | 2 | $42 |
| SRS Medical Systems, Inc. | 1 | $40 |
| Foundation Medicine, Inc. | 1 | $37 |
| ABC Home Medical Supply, Inc. | 2 | $33 |
| Convatec Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Myovant Sciences Inc. | 1 | $17 |
| Blue Earth Diagnostics | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Urogen Pharma, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Intuitive Surgical | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANKTIVA$2,500
- GENERAL KIDNEY STONE DISEASE$1,500
- AquaBeam Robotic System$1,245
- GENERAL - THERAPIES$550
- iTIND System$141
- XT CDX$119
How this compares
$6,922 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 25 | $348,780 |
| ErleadaApalutamide | 14 | $207,776 |
| NubeqaDarolutamide | 12 | $153,889 |
| OrgovyxRelugolix | 45 | $110,553 |
| Abiraterone Acetate | 78 | $106,644 |
| MyrbetriqMirabegron | 57 | $63,190 |
| GemtesaVibegron | 12 | $16,405 |
| Potassium Citrate ErPotassium Citrate | 36 | $7,200 |
| Tamsulosin Hcl | 392 | $7,163 |
| Finasteride | 250 | $4,791 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $1,312 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 53 | $1,139 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $1,124 |
| Prednisone | 67 | $470 |
| Chlorthalidone | 19 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $45 | $411,97082 claims |
| Johnson & JohnsonErleada | $16 | $207,77614 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $13 | $126,95857 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 urology providers in Minnesota.
Other urology in Woodbury
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Spencer HartWoodbury$69K
- Jodi MichaelsWoodbury$66K
- Mikhail RegelmanWoodbury$10K
- Samuel KieleyWoodbury$6K
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.